

## The Mitochondrial ARS (Mt-aaRS) Genes Annual Scientific Symposium 2022

February 10<sup>th</sup>, 2022

<b>Agenda</b>	
*Times are in Eastern Standard Time (EST). This agenda is subject to change and is tentative.	
Time Scheduled	Presenter Information
9:00 am	<b>Welcome &amp; Introduction</b> <b>Ali Fatemi, MD</b> Chief Medical Officer, Center for Leukodystrophies, Kennedy Krieger Institute
9:10 am	<b>CureARS Introduction</b> <b>Desiree Magee &amp; Ashley Rowland</b> Founders/Owners
9:15 am	<b>Clinical Presentations and molecular mechanisms of mtARS mutations</b> <b>Rita Horvath, MD, PhD</b> University of Cambridge, Horvath Laboratory
9:45 am	<b>Challenges of studying ARS2 defect in skin fibroblasts</b> <b>Johan Van Hove, MD</b> Children's Hospital Colorado
10:15 am	<b>The Power of Yeast for Functional Analysis of Novel Variants in Mitochondrial Aminoacyl-tRNA Synthetase</b> <b>Cristina Dallabona, Postdoctorate Researcher</b> University of Parma, Italy
10:30 am	<b>Live Q&amp;A</b> All panelists
10:45 am	<b>Break</b>
11:00 am	<b>Investigation of cell type specific effects of AARS2 and SARS2 patient mutations using stem cell derived models</b> <b>Henna Tynnismaa, PhD</b> University of Helsinki, Finland
11:30 am	<b>Investigating the role of seryl-tRNA synthetase [SARS2] in mitochondrial biology and recessive disease</b> <b>Christina Del Greco, PhD Student</b> University of Michigan, Anthony Antonellis Laboratory
12:00 pm	<b>YARS2 [Tyrosyl-tRNA synthetase] Project &amp; Modeling</b> <b>Rebecca Ganetzky, MD</b> Children's Hospital of Philadelphia <b>Ya-Ming Hou, PhD</b> Thomas Jefferson University
12:10 pm	<b>Live Q&amp;A</b> All panelists
12:20 pm	<b>Lunch Break</b>
1:15 pm	<b>Characterization of MARS2 Deficiency</b> <b>Bryn Webb, MD</b> University of Wisconsin-Madison
1:45 pm	<b>Fibroblast Studies in DARS2</b> <b>Jose Abdenur, MD</b>

Agenda	
*Times are in Eastern Standard Time (EST). This agenda is subject to change and is tentative.	
Time Scheduled	Presenter Information
	Children's Hospital of Orange County
2:15 pm	<b><i>Leukoencephalopathy with Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL) - A prototype disorder of mitochondrial tRNA Synthetases</i></b> <b>Amena Smith-Fine, MD &amp; Christina Mertz, PhD</b> Center for Leukodystrophies, Kennedy Krieger Institute <b>Marc Engelen, MD, PhD</b> Department of (Pediatric) Neurology, Amsterdam Leukodystrophy Center, Amsterdam UMC
3:00 pm	<b>Live Q&amp;A</b> All panelists
3:15 pm	<b>Break</b>
3:25 pm	<b><i>Mt-aaRS Patient Registry</i></b> <b>Alyssa Mendel, Research Project Manager</b> CoRDS (Coordination of Rare Disease Registry) at Sanford Health
3:30 pm	<b><i>Mt-aaRS research proposal overview and demonstration of the types of high-throughput and animal modeling experiments</i></b> <b>Neal Mathew, PhD</b> Children's Hospital of Philadelphia
3:40 pm	<b><i>Rare Disease Research &amp; Advocacy with Allstripes</i></b> <b>Richard Elles, PMP</b> Director of Patient Advocacy & Industry Engagement at Allstripes
3:45 pm	<b><i>Panel Discussion: Advances in Therapeutics</i></b>  <b><i>Introductory Comments and Quick Overview of Therapies in Development for Mitochondrial Disease</i></b> <b>Philip Yeske, PhD</b> United Mitochondrial Disease Foundation (UMDF)  <b><i>Precision Mitochondrial Medicine: Using preclinical models to identify therapeutic leads to evaluate in mitochondrial disease patients in the Mitochondrial Medicine Frontier Program</i></b> <b>Marni Falk, MD</b> Children's Hospital of Philadelphia  <b><i>Vatiquinone for Treatment of -ARS2 Disorders</i></b> <b>Matthew Klein, MD, MS, FACS</b> PTC Therapeutics  <b><i>Function™: A scalable platform to enable patient-centric drug discovery for rare diseases</i></b> <b>Christopher Moxham, PhD</b> Rarebase  <b><i>Commercial Laboratory Outreach Programs for Rare Diseases.</i></b> <b>Paul Kruszka, MD, FACG</b> GeneDx
5:00 pm	<b>Closing Remarks</b>